| Alliance Foot & Ankle Clinics Llc | |
|
6510 W Layton Ave, Greenfield, WI 53220-4563 | |
| (414) 282-7209 | |
| (414) 282-9948 |
| Full Name | Alliance Foot & Ankle Clinics Llc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 6510 W Layton Ave, Greenfield, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811306434 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 1026-25 (Wisconsin) | Primary |
| Provider Name | Donna J Hayes |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1225045651 PECOS PAC ID: 1456412543 Enrollment ID: I20120328001001 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices for heart failure, today announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD) – the world's first transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF).
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Five percent more cardiac infarctions detected and 11 percent fewer patients suffering a relapse. That is the result of a study of more than 80,000 patients in which two cardiac damage markers were compared with each other.
› Verified 7 days ago
| Provider Name | Ivelisse Vargas Jon |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1861627184 PECOS PAC ID: 9234388950 Enrollment ID: I20140114000917 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices for heart failure, today announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD) – the world's first transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF).
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Five percent more cardiac infarctions detected and 11 percent fewer patients suffering a relapse. That is the result of a study of more than 80,000 patients in which two cardiac damage markers were compared with each other.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alliance Foot & Ankle Clinics Llc 6510 W Layton Ave, Greenfield, WI 53220-4563 Ph: (414) 282-7209 | Alliance Foot & Ankle Clinics Llc 6510 W Layton Ave, Greenfield, WI 53220-4563 Ph: (414) 282-7209 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices for heart failure, today announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD) – the world's first transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF).
Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.
Five percent more cardiac infarctions detected and 11 percent fewer patients suffering a relapse. That is the result of a study of more than 80,000 patients in which two cardiac damage markers were compared with each other.
› Verified 7 days ago
Douglas L Kincaid Dpm Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 6186 W Layton Ave, Greenfield, WI 53220 Phone: 414-282-7209 Fax: 414-282-9948 | |
David John Labadie, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3717 S 56th St, Greenfield, WI 53220 Phone: 414-327-1119 | |
Douglas L Kincaid Dpm Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 6186 W Layton Ave, Greenfield, WI 53220 Phone: 414-282-7209 Fax: 414-282-9948 | |
Frank C Lavora, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 4448 W Loomis Rd, Ste 204, Greenfield, WI 53220 Phone: 414-281-1688 Fax: 414-281-8170 | |
Advanced Foot Specialists.llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3870 S 108th St, Greenfield, WI 53228 Phone: 414-327-2770 Fax: 414-327-0338 | |
Dr. Rosanne B Clement, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3870 South 108th Street, Greenfield, WI 53228 Phone: 414-327-2770 Fax: 414-327-0338 |